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Abstract Current therapies for glioblastoma (GBM) tar-
get bulk tumor through measures such as resection and
radiotherapy. However, recent evidence suggests that tar-
geting a subset of tumor cells, so-called cancer stem cells,
may be critical for inhibiting tumor growth and relapse.
The subventricular zone (SVZ), which lines the ventricles
of the brain, is thought to be the origin for the majority of
neural stem cells and potentially cancer stem cells.
Therefore, we assessed the relationship between tumor
contact with the SVZ as determined by MRI, cancer stem
cell gene expression and survival in 47 patients with GBM.
Using DNA microarrays, we found that genes associated
with cancer stem cells were not over-expressed in tumors
contacting the SVZ. Contact with the SVZ trended with
shorter survival (median 358 versus 644, P = 0.066).
Over-expression of CD133 (prominin-1) and maternal
embryonic leucine zipper kinase (MELK) was associated
with shorter survival, whereas mitogen activated protein
kinase 8 (MAPK8) was associated with longer survival
(P values 0.008, 0.005 and 0.002 respectively). Thus we
found no evidence of a stem-cell derived genetic signature
speciﬁc for GBM in contact with the SVZ, but there was a
relationship between stem cell gene expression and sur-
vival. More research is required to clarify the relationship
between the SVZ, cancer stem cells and survival.
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Introduction
Survival of patients with glioblastoma (GBM) remains
poor. Current therapy for gliomas is typically based on
cytoreductive strategies, such as surgery and radiotherapy,
which target the bulk of the tumor mass rather than speciﬁc
cell types [1]. Recently it has been suggested that a
minority of the cells in the tumor, so-called cancer stem
cells, account for most of the proliferation, growth and
radioresistance [2; reviewed in 3]. These cells can also
propagate tumors in vitro. Therefore the elimination of
these cancer stem cells may prove necessary to effect a
cure for glioma patients [4]. The subventricular zone
(SVZ), which lines the ventricles, maintains the ability to
generate neurons and glia throughout adulthood, and in
animal models, gliomas can be generated from this cell
population. It has been suggested that the SVZ is a source
for cancer stem cells that initiate gliomagenesis [5].
GBM are heterogeneous tumors, histopathologically,
radiographically and genetically [6]. Several genetic sub-
types have been characterized that are associated with
varying survival rates. For instance, an oligodendroglioma-
like genetic signature is associated with longer survival
[7, 8]. Survival also may be impacted by the tumor’s
relationship to the SVZ [9, 10]. Lim et al. [9] have sug-
gested that GBM contacting the SVZ are more likely to
recur as multifocal disease. And previously it has been
shown that multifocal disease is associated with shortened
survival [11]. It also has been proposed that GBM
contacting the SVZ may be more likely to be stem-cell-
derived, with potential impact on treatment decisions [9].
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identiﬁed. The most well-characterized, CD133, is associ-
ated with shortened survival [12]. However, to date, there
has been no analysis of gene expression and survival in
tumors based on contact with the SVZ. Therefore, we used
microarrays to analyze the relationship between tumors
associated with the SVZ, expression of cancer stem cell
and proliferative genes, and survival.
Materials and methods
Patient selection
All patients participating in this study signed institutional
review board-approved informed consent. Data acquisition
was performed in compliance with all applicable Health
Insurance Portability and Accountability Act (HIPAA)
regulations. Patients were retrospectively selected from
our institution’s neuro-oncology database. All patients
(n = 47) who met the following criteria were selected: (1)
pathology conﬁrmed GBM (2) baseline (pre-surgical) MRI
(3) fresh-frozen tissue adequate for microarray analysis.
All patients were treated with radiation therapy (RT; 6000
± 500 cGy) and subtotal/total resection at time of initial
tumor presentation. Accrual dates for this study were
October 1999 to January 2004. A total of 26/47 (55.3%)
patients received adjuvant chemotherapy, most commonly
temozolomide (15/47, 31.9%). Some patients also received
salvage chemotherapy.
Imaging
MRI sequences were acquired on a 1.5T scanner and typ-
ically included axial T1 weighted (TR 400, TE 15, slice
thickness 5 mm), T2 weighted fast spin-echo (TR 4000, TE
126-130, slice thickness 5 mm), diffusion-weighted and
gadopentetate dimeglumine enhanced (Magnevist; Berlex,
Wayne, NJ; 0.1 mmol/kg) axial and coronal T1 weighted
images (TR 400, TE 15, slice thickness 3 mm), with a ﬁeld
of view of 24 cm and a matrix size of 256 9 256. Post-
contrast images were acquired immediately after contrast
injection. The contrast-enhancing tumor was assessed for
contact with the SVZ and cortex as described in [9].
Tumors were segregated into 4 groups by a neuroradiolo-
gist (W.P.): group I, tumor contacting SVZ and inﬁltrating
cortex 9 (n = 13); group II, tumor contacting SVZ but not
involving the cortex (n = 12); group III, tumor involving
cortex but not contacting the SVZ (n = 16); group IV,
tumor involving neither SVZ nor cortex (n = 6; Fig. 1).
A minority of patients had multifocal disease at initial
presentation (7/47, 15%). For these patients, the scans were
graded according to the dominant tumor nodule.
Microarray data
RNA was puriﬁed from fresh frozen tumor biopsies and
was hybridized to U133A and U133 Plus 2.0 Arrays at our
DNA Microarray Facility. The data ﬁles generated were
normalized using RMA from Bioconductor (for R, version
2.6; http://cran.r-project.org/bin/windows/base/), relative to
Fig. 1 Tumor grading. Group I
(a), tumor contacting SVZ and
inﬁltrating cortex (n = 13);
group II (b), tumor contacting
SVZ but not involving the
cortex (n = 12); group III
(c), tumor involving cortex but
not contacting the SVZ
(n = 16); group IV (d), tumor
involving neither SVZ nor
cortex (n = 6)
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123other Affymetrix microarrays of the same platform using
the Celsius Database (http://www.ncbi.nlm.nih.gov/pub
med/17570842). Only probes from the U133A portion
that were retained in U133 Plus 2.0 arrays were analyzed
for each sample. RMA normalized data was imported into
dChip [12] for differential expression analysis among
genes in different SVZ groups. We compared the fold
change for the mean of each gene in the different SVZ
groups, and used a t-test to assess the signiﬁcance. Sig-
niﬁcant genes were further analyzed by the DAVID
bioinformatics tool (The US National Institutes of Health
(NIH) Database for Annotation, Visualization and Inte-
grated Discovery; http://david.abcc.ncifcrf.gov;[ 13, 14]),
to identify enriched biological groups [15].
Heat map generation
Gene expression was visualized through heat maps gener-
ated by dChip. Differentially expressed genes identiﬁed
among the SVZ groups were hierarchically clustered, while
the samples were arranged by SVZ group.
Statistical methods
The survival library from R (version 2.6; http://cran.
r-project.org) and the Cox proportional hazards model were
used to analyze the relationship between gene expression
and survival. Results for all genes were obtained and the
values for the stem cell genes of interest, and the differ-
entially expressed genes for the SVZ groups were extrac-
ted. Cox model regression analysis results were obtained
for each of the genes and a transformed hazard ratio
(Z score, the ratio of the regression coefﬁcient to the
standard error) was generated. A positive score Z coefﬁ-
cient indicates higher expression corresponding to higher
hazard rate and shorter survival, and lower expression
corresponding to a lower hazard rate and longer survival.
Kaplan–Meier curves with log-rank test were used to
analyze survivability patterns between SVZ grades and
gene expression. Expression fold change between tumor
groups was computed with a fold change threshold of 1.2
with a lower 90% conﬁdence bound, and a t-test P value of
0.05. For most analyses, a P value of\0.05 was accepted
as signiﬁcant. Some analyses were performed with a
Bonferroni correction for multiple testing.
Results
Poor correlation of stem cell gene expression
A total of 7 genes of interest related to cancer stem cells
or tumor proliferation, based on previous literature [12,
16–20], were selected for analysis. The genes were CD133
(prominin1), maternal embryonic leucine zipper kinase
(MELK), bone morphogenetic protein 4 (BMP 4), E2F
transcription factor 2 (E2F 2), mitogen-activated protein
kinase 8 (MAPK 8; also known as Jun NH2-terminal
kinase), OLIG2, and nestin (NES). We attempted to ﬁnd a
stem cell signature which consisted of a number of genes
whose expression correlated highly with one another or
over expression of stem cells genes in a speciﬁc tumor
group, but found none. The correlation matrix showed very
low correlation between any of the stem cell genes of
interest (Table 1). Lack of correlation is conﬁrmed on the
heat map (Fig. 2).
Stem cell genes associated with survival
In the survival analysis (Cox Model), 6 of the 7 genes of
interest had at least one probe with a P value signiﬁcant at
the 0.05 level. With a multiple testing correction for the 9
probes, 2 of these genes (MAPK8 and MELK) are signif-
icantly associated with survival at a Bonferroni adjusted P
value of 0.006 (Table 2). Increased expression levels of
CD133 and MELK were associated with shorter survival,
Table 1 Correlation of stem cell gene expression in 47 patients with GBM
CD133 MELK E2F2 MAPK8 (P 1
a) MAPK8 (P 2) BMP4 OLIG2 (P 1) OLIG2 (P 2) NES
CD133 – 0.22 -0.17 -0.21 -0.11 -0.24 -0.09 -0.06 0.04
MELK 0.22 – 0.22 -0.03 0.06 0.04 -0.14 -0.07 0.36
E2F2 -0.17 0.22 – 0.53 0.52 0.53 -0.16 -0.20 0.06
MAPK8 (PS 1) -0.21 -0.03 0.53 – 0.81 0.43 0.13 0.22 -0.02
MAPK8 (PS 2) -0.11 0.06 0.52 0.81 – 0.27 0.17 0.13 -0.01
BMP4 -0.24 0.04 0.53 0.43 0.27 – -0.17 -0.13 0.15
OLIG2 (PS 1) -0.09 -0.14 -0.16 0.13 0.17 -0.17 – 0.77 -0.05
OLIG2 (PS 2) -0.06 -0.07 -0.20 0.22 0.13 -0.13 0.77 – -0.11
NES 0.04 0.36 0.06 -0.02 -0.01 0.15 -0.05 -0.11 –
a P probe. Both MAPK8 and OLIG2 had 2 probes available for analysis
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123whereas increased expression levels of nestin, OLIG2,
BMP4, ETF2 and MAPK8 were associated with longer
survival.
Differentially expressed genes in group II tumors:
association with immune system not cancer stem cells
Although we did not ﬁnd that stem cell gene expression was
increased in tumors contacting the SVZ, several other genes
were over-expressed in tumors contacting the SVZ. The list
of differentially expressed genes was submitted to the
DAVID bioinformatics tool in order to look at over repre-
sented functional groups and to determine general function.
Of the 33 genes (36 probes) over-expressed in group II
tumors, 7 showed a Gene Ontology (GO) term of the
immune system process (P value = 0.03). These non stem-
cell genes were: FCGR3A, HLA-DRB5, BCL6, FCGR3B,
MAFB, HLA-DRA, HLA-E. These genes all had higher
expression in the group II, with a fold change ranging from
1.48 to 2.43 (Table 3). The average fold change of the 7
immune system differentially expressed genes was 1.82.
Figure 3 is a heat map showing gene expression by SVZ
grade. Note the high expression of these immune-related
genes in group II tumors. We alsoassessed the expression of
these genes in group IV versus groups I and III, since group
IV tumors also lack cortical involvement. Except for BCL6,
the immune genes were all over-expressed in group IV
tumors with fold changes ranging from 1.31 to 2.31.
Association of genes overexpressed in SVZ-contacting
tumors and survival
We also analyzed the relationship between genes over-
expressed in group II tumors and survival (Table 4).
Expression of 5 genes (either increased or decreased)
correlated with shorter survival. Comparing gene expres-
sion in tumors grade I and II versus III and IV (i.e., all
tumors that contact the SVZ versus all that do not), led to
the identiﬁcation of CARM1 which is highly expressed in
SVZ-contacting tumors and also is highly correlated with
survival (P = 0.005). Thus this analytic approach may be
Fig. 2 Heat map of stem cell
probes across group I–IV. Red
corresponds to higher gene
expression levels. Patient
samples noted along top row
Table 2 Stem cell/proliferative gene expression and survival
Gene Z
a P value
b,c
Gene symbol Probe
MAPK8 210477_x_at -3.17 0.002
MAPK8 210671_x_at -2.46 0.014
BMP4 211518_s_at -2.11 0.035
NES 218678_at -2.11 0.035
OLIG2 213825_at -1.98 0.048
OLIG2 213824_at -1.51 0.130
E2F2 207042_at -1.36 0.170
CD133 204304_s_at 2.65 0.008
MELK 204825_at 2.79 0.005
a Z is the transformed hazard ratio. A negative Z score indicates
higher expression levels are correlated with longer survival, and a
positive Z score indicates higher expression is correlated with shorter
survival
b P value from Cox model
c Values\0.05 bolded
Table 3 Immune system genes over-expressed in group II tumors
Gene symbol Fold change 90% CI P value
a,b
FCGR3A 2.43 1.49–3.73 0.020
BCL6 2.05 1.43–2.80 0.013
HLA-DRA 1.79 1.20–2.51 0.039
HLA-DRB5 (PS 2) 1.78 1.20–2.54 0.037
HLA-DRB5 (PS 1) 1.77 1.21–2.48 0.033
MAFB 1.67 1.25–2.23 0.011
HLA-E (PS 1) 1.56 1.27–1.93 0.002
HLA-E (PS 2) 1.48 1.24–1.76 0.002
PS probes
a P value from Cox model
b Values\0.05 bolded
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123of use in screening for genes that may impact the rela-
tionship between SVZ contact and survival.
Kaplan–Meier analysis
We generated Kaplan–Meier curves to compare survival
between tumors in group I and II versus III and IV. There
was a trend towards shorter survival (median survival 358
versus 654 days, P = 0.066; Fig. 4). There was no sig-
niﬁcant difference in survival curves for group II versus I,
III, IV (Fig. 4). There was no statistically signiﬁcant
difference between rates of multifocal disease, at presen-
tation and recurrence, between groups. However, there was
a signiﬁcant difference between gross total resection rates
in group I versus remainder tumors (Table 5). Figure 5
shows Kaplan–Meier curves for patients grouped by gene
expression.
Discussion
It has been hypothesized that gliomas arise from stem cells
originating in the SVZ. Previously it has been reported that
more aggressive patterns of GBM recurrence are associated
with tumors that contact the SVZ, and that these tumors
may express a ‘‘stem-cell-derived’’ phenotype that could
impact treatment decisions [9]. Therefore we analyzed the
relationship between expression of cancer stem-cell genes,
contact of tumor with the SVZ and patient survival.
Similar to previous work [9, 10], we found that patients
with GBM which contacted the SVZ trended with shorter
survival. One possibility is that shortened survival may be
related to tumor size, as tumors that contact both the cortex
and SVZ tend to be large. However, previous reports have
shown little correlation between GBM size and survival
[11]. Additionally, Barami et al. [21] found that contact
with the ventricular wall was independent of size.
Another possibility is that tumors that contact the SVZ
have higher rates of multifocal or subependymal/leptome-
ningeal spread. We did not ﬁnd a signiﬁcant difference in
rates of non-local recurrence between tumor groups based
Fig. 3 Heat map of
differentially expressed genes
between group II tumors versus
the remainders. Note that
several immune related genes
(blue) show higher expression
in group 2 tumors. Red
corresponds to higher gene
expression levels
Table 4 Genes over-expressed in group II tumors that correlate with
survival
Gene
symbol
Z
a P value Fold
change
90% CI
b P value
FC
c,d,e
COL5A2 3.15 0.002 2.03 1.30–3.11 0.026
LOXL2 3.10 0.002 2.29 1.31–3.57 0.046
SLIT2 2.42 0.016 2.04 1.30–2.99 0.034
SOX11 2.37 0.018 -2.74 -1.37–8.14 0.024
TTK 2.32 0.020 -1.61 -1.23–2.07 0.010
a Z is the transformed hazard ratio. A negative Z score indicates
higher expression levels are correlated with longer survival, and a
positive Z score indicates higher expression is correlated with shorter
survival
b CI Conﬁdence interval
c FC fold change
d P value from Cox model
e Values\0.05 bolded
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123on SVZ contact. And only one patient had leptomeningeal
recurrence. Unlike Lim et al. [9] we found that group III
tumors had the highest rates of multifocal disease, both at
initial presentation and at recurrence. Thus it is unclear if
tumors that contact the SVZ have more aggressive patterns
of recurrence. Small sample sizes may account for these
discordant results.
There was a difference in gross total resection rates
between groups. Group I tumors (those that contact both
the ventricle and cortex) had a lower gross total resection
rate than other tumors. Since complete resection is asso-
ciated with better survival [22], this could be a potential
confound for the survival data. Additionally, deeper tumors
may have more impact on critical structures, increasing
their impact on disability. Thus we cannot say whether
tumors that contact the SVZ are intrinsically more malig-
nant than those that do not.
We found no relationship between stem-cell gene
expression and SVZ grade. Speciﬁcally there was no cor-
relation in expression between the selected stem cell genes,
and there was no enrichment of stem cell genes in tumors
that contacted the SVZ. Although not correlated with tumor
location, expression of several stem cell genes, including
CD133, was associated with shortened survival, similar to
previous reports [12, 23]. For instance, Zhang et al. [23]
found that CD133 expression was negatively correlated
with both overall survival and progression-free survival.
CD133 expression has been shown to be associated with
resistance to radiation and chemotherapy [24]. Similar
results have been demonstrated in mice models of GBM
[25]. Interestingly, BMP4 has been hypothesized to down-
regulate CD133 and increase survival in a mouse model
[26]. Although there was no signiﬁcant correlation between
CD133 and BMP4 expression, increased BMP4 expression
was associated with longer survival.
Unlike the report of Zhang et al. [23] we found that
higher nestin expression was associated with longer sur-
vival. Some differences between the two experiments are
notable. Zhang measured protein level with immunohisto-
chemistry, whereas we examined gene expression. Zhang
also looked at grade II–IV tumors, whereas we restricted
our analysis to grade IV tumors (GBM). Another group
[27] found no difference in survival based on nestin
expression levels. Similarly, increased OLIG2 expression
was associated with longer survival. OLIG2 is associated
with oligodendrogliomal lineage development [17], and an
oligodendroglioma component and genetic signature have
previously been shown to be associated with longer sur-
vival [28]. Another gene whose expression was associated
with longer survival was MAPK8 (also known as JNK).
Previously it has been shown that in cultured glioma cells,
inhibition of this kinase reduces VEGF secretion [29].
Fig. 4 Kaplan–Meier curves of
group II versus groups I, III and
IV combined (a) and Kaplan–
Meier curves of group I and II
combined versus groups III and
IV combined (b)
Table 5 Clinical data by tumor group
Group I II III IV
n 13 12 16 6
Age (SE
a) 54 (4.5) 48.8 (2.5) 50.6 (3.7) 44 (4.5)
KPS
b (SE) 83.8 (4.6) 80.8 (5.1) 85 (4.2) 88 (7.3)
Adj chemo
c (%) 6/13 (46.2) 8/12 (66.7) 9/16 (56.3) 3/6 (50.0)
Temozolomide
d
(%)
2/13 (15.4) 4/12 (33.3) 7/16 (43.8) 2/6 (33.3)
GTR
e,f (%) 2/13 (15.4) 6/12 (50.0) 7/16 (43.8) 4/6 (66.7)
Multifocal,
initial (%)
1/13 (7.7) 1/12 (8.3) 4/16 (25.0) 1/6 (16.7)
Multifocal,
relapse
g (%)
3/11 (27.3) 1/8 (12.5) 4/13 (30.8) 1/5 (20.0)
a SE standard error
b KPS Karnosfsky performance status at presentation
c adj chemo adjuvant chemotherapy of any kind
d temozolomide adjuvant chemotherapy with temozolomide
e GTR gross total resection
f P = 0.03 for group I versus other tumors, chi-square test
g Six patients have yet to progress, and follow-up scans were not
available for 4 patients, accounting for reduced patient number for
this variable
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123Since VEGF is associated with malignancy, this may
explain why patients with tumors with lower MAPK8 gene
expression had longer survival.
Since patients in group I ? II trended with shorter sur-
vival, we also analyzed the expression of genes in SVZ-
contacting tumors compared to those that did not contact
the SVZ in order to look for candidate genes that may be
involved with shorter survival. Several genes, including
CARM1 and LOXL2, over-expressed in SVZ-contacting
tumors, were associated with poor survival. LOXL2 has
been shown to promote cell migration in breast cancer [30],
and is associated with a poor prognosis in squamous cell
carcinomas [31], but this is the ﬁrst report of an association
with poor survival in GBM. CARM1 promotes breast
cancer proliferation through an estrogen-dependent mech-
anism [32], but has no known role in glioma malignancy.
Interestingly, although no stem-cell gene expression
signature was associated with SVZ group II, many genes
associated with the immune system were over-expressed in
group II, including several MHC genes. This is of potential
Fig. 5 Kaplan–Meier curves
for selected genes: a MAPK8,
b CD133, c BMP-4, d MELK,
e CARM1 and f LOXL2. For all
graphs the dashed line indicates
survival data for patients with
greater than median gene
expression levels, and the solid
line is for patients with less than
median gene expression levels.
Note that increased levels of
MAPK and BMP-4 expression
are associated with longer
survival, whereas increased
CD133 and MELK expression
levels correlate with shorter
survival. Increased CARM1 and
LOXL2 (enriched in SVZ-
contacting tumors) also are
correlated with poorer survival
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123importance as MHC expression modulates response to
dendrictic cell therapy currently being developed to treat
GBM, and thus tumors that contact the SVZ may respond
differently to this treatment compared to other tumors [33].
Additionally, it has been shown that migrating glioma cells
down-regulate MHC class II genes. If the SVZ is the origin
for gliomagenic cells, this suggests that high expression of
these genes may account for the lack of spread of group II
tumor progenitor cells away from the SVZ prior to tumor
formation [34].
In conclusion, we found no evidence that tumors con-
tacting the SVZ were more likely, based on gene expres-
sion, to be ‘‘stem-cell-derived’’, than tumors not contacting
the SVZ. Two possible explanations are: (1) the SVZ is not
the origin for tumor producing cells; or (2) cells responsible
for gliomagenesis are produced in the SVZ but migrate
towards the cortex before tumorigenesis. The second
hypothesis is supported by animal studies which have
shown that gliomas arising from the periventricular region
can grow along white matter tracts, losing their connection
to the SVZ [35]. We did ﬁnd, however, that SVZ-contacting
cells over-expressed several genes associated with patient
survival and with the immune system. The expression of
immune-related genes could impact response to treatment,
and may mediate cell migration away from the SVZ. Thus,
more research is required to clarify the relationship between
migration of SVZ derived cancer stem cells and the tem-
poral relationship to gliomagenesis.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
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